{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:46:21Z","timestamp":1778323581270,"version":"3.51.4"},"reference-count":23,"publisher":"Impact Journals, LLC","issue":"59","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,11,21]]},"DOI":"10.18632\/oncotarget.22222","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T20:12:51Z","timestamp":1509567171000},"page":"100326-100338","source":"Crossref","is-referenced-by-count":22,"title":["Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy"],"prefix":"10.18632","volume":"8","author":[{"given":"Shariful","family":"Islam","sequence":"first","affiliation":[{"name":"Cancer Biology GIDP, University of Arizona Cancer Center, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Vick","sequence":"additional","affiliation":[{"name":"West Cancer Center and University of Tennessee Health Sciences Center, Memphis, TN 38163, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Huber","sequence":"additional","affiliation":[{"name":"West Cancer Center and University of Tennessee Health Sciences Center, Memphis, TN 38163, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Morales","sequence":"additional","affiliation":[{"name":"West Cancer Center and University of Tennessee Health Sciences Center, Memphis, TN 38163, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Spier","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, University of Arizona, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Cooke","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Arizona Cancer Center, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Weterings","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Arizona, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daruka","family":"Mahadevan","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Arizona Cancer Center, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"2","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","article-title":"Therapeutic options in relapsed or refractory peripheral T-cell lymphoma","volume":"40","author":"Tilly","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-hodgkin lymphoma: Southwest Oncology Group Study S0350","volume":"119","author":"Miller","year":"2013","journal-title":"Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.leukres.2012.10.017","article-title":"Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment","volume":"37","author":"Mahadevan","year":"2013","journal-title":"Leuk Res"},{"key":"5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1517\/17460441.2011.555395","article-title":"Update on aurora kinase targeted therapeutics in oncology","volume":"6","author":"Mahadevan","year":"2011","journal-title":"Expert Opin Drug Discov"},{"key":"6","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-11-2413","article-title":"Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma","volume":"18","author":"Qi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas","volume":"32","author":"Bernstein","year":"2014","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ligon","year":"2015","journal-title":"N Engl J Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.oraloncology.2014.11.014","article-title":"Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma","volume":"51","author":"Azuma","year":"2015","journal-title":"Oral Oncol"},{"key":"11","first-page":"444","article-title":"Essential roles of mTOR\/Akt pathway in Aurora-A cell transformation","volume":"5","author":"Ouchi","year":"2009","journal-title":"Int J Biol Sci"},{"key":"12","article-title":"Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-\u03b4,\u03b3, in patients with relapsed\/refractory lymphoma","author":"Kahl","year":"2013","journal-title":"2013 ASCO Annual Meeting. J Clin Oncol"},{"key":"13","first-page":"339","article-title":"Multiple roles of the PI3K\/PKB (Akt) pathway in cell cycle progression","volume":"2","author":"Slingerland","year":"2003","journal-title":"Cell Cycle"},{"key":"14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3324\/haematol.2012.068510","article-title":"Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas","volume":"98","author":"Alves","year":"2013","journal-title":"Haematologica"},{"key":"15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.V126.23.341.341","article-title":"First multicenter, randomized phase 3 study in patients (Pts) with relapsed\/refractory (R\/R) peripheral T-cell lymphoma (PTCL): alisertib (MLN8237) versus investigator's choice (Lumiere trial; NCT01482962)","volume":"126","author":"d'Amore","year":"2015","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood.V126.23.1560.1560","article-title":"Aurora plus PI3K inhibition abrogates PD-L1 induction in peripheral T-cell non-Hodgkin lymphoma","volume":"126","author":"Qi","year":"2015","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/13543784.2012.640318","article-title":"CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies","volume":"21","author":"Winer","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/OTT.S34641","article-title":"Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies","volume":"7","author":"Bishop","year":"2014","journal-title":"Onco Targets Ther"},{"key":"19","doi-asserted-by":"publisher","first-page":"e95184","DOI":"10.1371\/journal.pone.0095184","article-title":"Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2","volume":"9","author":"Qi","year":"2014","journal-title":"PLoS One"},{"key":"20","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1182\/blood.V118.21.4963.4963","article-title":"Phosphatidylinsoitol-3 kinase delta (PI3K\u03b4) inhibitor AMG 319 combined with vincristine enhances G2\/M arrest and apoptotic death in neoplastic B cells","volume":"118","author":"Sinclair","year":"2011","journal-title":"Blood"},{"key":"21","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1182\/blood-2010-11-315705","article-title":"The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia","volume":"117","author":"Johnson","year":"2011","journal-title":"Blood"},{"key":"22","doi-asserted-by":"publisher","first-page":"e96801","DOI":"10.1371\/journal.pone.0096801","article-title":"IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples","volume":"9","author":"De","year":"2014","journal-title":"PLoS One"},{"key":"23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T14:57:52Z","timestamp":1589209072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":23,"journal-issue":{"issue":"59","published-print":{"date-parts":[[2017,11,21]]}},"alternative-id":["22222","29245981"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.22222","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,1]]}}}